FDA Clears AutoGenomics' CYP2C19 Assay | GenomeWeb

This article has been updated to clarify the intended use of the assay.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AutoGenomics today said that the US Food and Drug Administration has given 510(k) clearance for its Infiniti CYP2C19 assay.

The test detects three genetic variants, *2, *3, and *17 of the CYP450 2C19 gene. The test is for use on AutoGenomics' Infiniti Analyzer molecular diagnostic platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.